Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors April 29, 2025 7:27 AM EDT | Source: Cardiol Therapeutics Inc. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration ("US FDA") to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of th ...

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent PericarditisApril 16, 2025 7:27 AM EDT | Source: Cardiol Therapeutics Inc.Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Ap ...

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients with acute myocarditis, with topline data expected in Q2 2025 CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis, which includes recurrent pericarditis Cash and c ...

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart FailureData demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failureFebruary 20, 2025 7:27 AM EST | Source: Cardiol Therapeutics Inc.Tor ...

Cardiol Therapeutics President and CEO, David Elsley NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company's lead oral drug, CardiolRx™, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at high risk for recurrence. Cardiol Therapeutics is a clinical-stage life sciences company focused on the research a ...

Cardiol Therapeutics President and CEO, David Elsley NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company’s lead oral drug, CardiolRx™, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at high risk for recurrence. Cardiol Therapeutics is a clinical-stage life sciences company focused on the research a ...

Known for their uncommonly pronounced risk/reward profile, penny stocks all too often entice investors with their low prices and potential for significant returns, only to fail to live up to those expectations. The world of penny stocks is also characterized by pump-and-dump and other scams, facilitated by the fact that most penny stock companies do not have an extensive history of financial reporting or an established brand name and presence. This is all to say that investors should be cautious of any penn ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024November 18, 2024 11:37 AM EST | Source: Cardiol Therapeutics Inc.Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week studyEpisodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 ...

NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector. Cardiol’s focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate CardiolRx™, positions it as a pioneer in addressing ma ...